

**The membrane protein Amuc\_1098 from *Akkermansia muciniphila* alleviates acute pancreatitis via TLR2 signaling and glycerophospholipid metabolism remodeling**

**Running title: Amuc\_1098 attenuates acute pancreatitis**

Lijuan Wang<sup>1,†</sup>, Ruilin Zhang<sup>1,†</sup>, Liangtao Zhao<sup>2,†</sup>, Liuxiang Xiao<sup>1</sup>, Xiaoyan Zhang<sup>1</sup>, Lingyi Liu<sup>1</sup>, Jiaju Wang<sup>1</sup>, Kuiyuan Chen<sup>1</sup>, Jinyang Li<sup>1</sup>, Maosen Zhang<sup>3,\*</sup>, Jie Li<sup>4,\*</sup>, Wei Lin<sup>1,\*</sup>

<sup>1</sup> School of Medicine, Nanjing University of Chinese Medicine, Nanjing Drum Tower Hospital, Nanjing 210023, China.

<sup>2</sup> Hepato-Pancreato-Biliary Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China

<sup>3</sup> Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, China

<sup>4</sup> Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, 210000, China

**\* Corresponding author:**

Wei Lin, email: [weilin@njucm.edu.cn](mailto:weilin@njucm.edu.cn)

Jie Li, email: [lijier@nju.edu.cn](mailto:lijier@nju.edu.cn)


Maosen Zhang, email: [zms1973@yeah.net](mailto:zms1973@yeah.net)

Tel: +86-13917220653

Fax: +86-25-85811925


<sup>†</sup> These authors contributed equally to this work.

## Supplementary Figures and Tables



**Supplementary Fig. 1: Expression and purification of Amuc\_1098 *in vitro*.**


**a** Purified Amuc\_1098 was stained by Coomassie brilliant blue. **b** Purified Amuc\_1098 was additionally detected by western blot.



**Supplementary Fig. 2: Amuc\_1098 mitigates pancreatic inflammatory injury in L-Arg-induced AP mice via TLR2 mediation.**

**a** Schematic diagram of the experimental study design. Acute pancreatitis was induced in the mice by intraperitoneal injection with 8.8% L-Arg. We administered Amuc\_1098 (3 µg/mouse) in sterile phosphate buffer saline (PBS) supplemented with 2.5% glycerol to mice daily for a total of 20 days prior to L-Arg treatment. TLR2-siRNA (2.5 nM) was intraperitoneally injected into mice to construct TLR2 knockdown mice on the last day. **b** Body weight. **c** Representative histopathological sections with H&E staining of


pancreatic tissue from mice. All images were amplification 400. The mRNA expression of proinflammatory cytokines in the pancreas, including TNF- $\alpha$  (d), IL-1 $\beta$  (e), and IL-6 (f). g Western blot was used to measure NF- $\kappa$ B signaling pathway among three groups. The grayscale values of IKK $\beta$  (h), IKB $\alpha$  (i), p-IKB $\alpha$  (j), p65 (k), p-p65 (l) by Western blot.  $\beta$ -tubulin was used as an internal standard. Data are shown as mean  $\pm$  SEM, with six biologically independent mice included in each experimental group. Significance was determined by one-way ANOVA and Tukey's multiple comparisons test.



**Supplementary Fig. 3: Amuc\_1098-mediated protection against pancreatic injury was significantly attenuated in TLR2-deficient mice with acute pancreatitis.**


Following a 20-day pre-treatment with Amuc\_1098 (3  $\mu$ g/mouse in PBS/2.5% glycerol), acute pancreatitis was induced in TLR2-KO mice by intraperitoneal injection of caerulein (50  $\mu$ g/kg, 10 hourly injections) together with LPS (5 mg/kg at the last caerulein injection). **a** Pancreas weight. Serum levels of amylase (**b**) and lipase (**c**) were measured. **d** Representative images of H&E-stained pancreatic tissue sections showing histopathological changes (original magnification,  $\times 400$ ). Pancreatic mRNA expression of the proinflammatory cytokines TNF- $\alpha$  (**e**), IL-1 $\beta$  (**f**), and IL-6 (**g**) was analyzed. **h** Western blot analysis was performed to assess key proteins in the NF- $\kappa$ B signaling pathway across the four groups, using  $\beta$ -tubulin as an internal control. Data are shown

as mean  $\pm$  SEM, with five biologically independent mice included in each experimental group. Significance was determined by one-way ANOVA and Tukey's multiple comparisons test.




**Supplementary Fig. 4: Amuc<sub>1098</sub><sup>\*</sup> inhibited the release of inflammatory cytokines from AR42J cells *in vitro*.**

To construct the AP cell model, AR42J cells were treated with 10 mg/mL L-Arg for 12 h. Then the cells were exposed to Amuc<sub>1098</sub><sup>\*</sup> ranging from 0.05 to 10  $\mu$ g/mL for 72 h. The production of TNF- $\alpha$  (a), IL-1 $\beta$  (b), IL-6 (c), MCP-1 (d) in AR42J cell culture supernatant. e The mRNA expression of proinflammatory cytokines in AR42J cells, including TNF- $\alpha$ , IL-1 $\beta$ , IL-6. f Western blot analyses of NF- $\kappa$ B signal pathway in AR42J cells. Data are expressed as the mean  $\pm$  SEM, with each data point representing one biological replicate (n = 3 per group). Significance was analyzed using one-way ANOVA and Tukey's multiple comparisons test.




**Supplementary Fig. 5: Amuc\_1098 inhibited the NF- $\kappa$ B signaling pathway in MPC-83 cells through TLR2.**

The protein levels of TLR2 (a), IKK $\beta$  (b), IKB $\alpha$  (c), p-IBK $\alpha$  (d), p65 (e), p-p65 (f) after overexpression of TLR2 in MPC-83 cells treated with different concentrations of Amuc\_1098. The expression of TLR2 (g), IKB $\alpha$  (h), p-IBK $\alpha$  (i), p65 (j), p-p65 (k) after TLR2 knockdown in MPC-83 cells treated with different concentrations of Amuc\_1098. Data are presented as the mean  $\pm$  SEM (n = 3 biologically independent samples per group). Significance was analyzed using one-way ANOVA and Tukey's multiple comparisons test.




**Supplementary Fig. 6: Amuc\_1098 intervention in AP mice induced by L-Arg could improve Splenic inflammation.**

**a** Spleen weight. The mRNA expression of  $TNF-\alpha$  (**b**),  $IL-1\beta$  (**c**), and  $IL-6$  (**d**) in the spleen. **e** Immunoblotting was performed to assess the expression of key NF- $\kappa$ B signaling components, using antibodies specific for IKK $\beta$ , IKB $\alpha$ , phospho-IKB $\alpha$ , p65, and phospho-p65.  $\beta$ -Tubulin was employed as an internal control. Analysis of IKK $\beta$  (**f**), IKB $\alpha$  (**g**), p-IKB $\alpha$  (**h**), p65 (**i**) and p-p65 (**j**) relative protein expression based on gray values. Data are shown as mean  $\pm$  SEM, with  $n = 6$  biologically independent mice per group. Significance was determined by one-way ANOVA and Tukey's multiple comparisons test.




**Supplementary Fig. 7: Amuc\_1098 failed to alleviate splenic inflammation in TLR2-deficient mice during acute pancreatitis.**

Serum levels of the inflammatory cytokines TNF-α (a), IL-1β (b), IL-6 (c), and MCP-1 (d) were measured in TLR2-knockout mice. e Spleen weight. The mRNA expression of TNF-α (f), IL-1β (g), and IL-6 (h) in the spleen. i Immunoblotting was performed to assess the expression of key NF-κB signaling components, using antibodies specific for IKKβ, IKBα, phospho-IKBα, p65, and phospho-p65. β-Tubulin was employed as an internal control. Data are shown as mean ± SEM, with n = 5 biologically independent mice per group. Significance was determined by one-way ANOVA and Tukey's multiple comparisons test.



**Supplementary Fig. 8: Effect of Amuc\_1098 on colonic tight junction proteins in TLR2-KO mice.**


**a** Immunoblotting was performed to detect tight junction proteins (CD2AP, Occludin, Claudin-1) in colon tissues of TLR2-KO mice, using  $\beta$ -tubulin as an internal control. Relative expression levels are presented for CD2AP (**b**), Occludin (**c**), and Claudin-1 (**d**). Data are shown as mean  $\pm$  SEM, with  $n = 5$  biologically independent mice per group. Significance was determined by one-way ANOVA and Tukey's multiple comparisons test.



**Supplementary Fig. 9: Amuc\_1098 targeted TLR2 to regulated tight junction pathway in Caco-2 cells.**

To establish a barrier dysfunction model, Caco-2 monolayers are treated with LPS (1 μg/mL, 24 h) and then with Amuc\_1098 (0.05–10 μg/mL, 72 h). **a** The expression levels of proteins associated with the tight junction signaling pathway were assessed by western blotting. **b** Single staining of Caco-2 cells. Blue, DAPI; red, CD2AP or Claudin-1 or Occludin. Scale bars, 100 μm. **c** The level of proteins related to tight junction signaling pathway after overexpression of TLR2 in Caco-2 cells treated with different concentrations of Amuc\_1098. **d** The protein expression of tight junction






**Supplementary Fig. 11: Effects of Amuc\_1098 on serum metabolic profiling in mice with AP.**


**a-d** Spatial metabolomics was used to detect pancreatic tissue metabolism in mice. PLS-DA score (**a-b**) and differential metabolite Volcano Plot (**c-d**) among control, AP and AP+Amuc\_1098 groups. **e-h** Serum metabolites of mice were detected by non-target metabolomics. **e** PLS-DA score among control, AP and AP+Amuc\_1098 groups. **f** Venn diagram of differential metabolites in three groups. **g** Pie chart of classification of metabolites between AP and Control. The effects of Amuc\_1098 on levels of PC (15:0/0:0) (**h**) and 2-Stearoylglycerophosphoglycerol (**i**) in serum of mice. **j-n**, Lipidomics was used to detect serum lipid metabolism in mice. Differential metabolite Volcano Plot (**j-k**), KEGG topology analysis (**i-m**) and radar picture (**n**) among Control,

AP and AP+Amuc\_1098 group. Data are presented as the mean  $\pm$  SEM (n = 6 biologically independent samples per group) and were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test.



**Supplementary Fig. 12: Effects of Amuc\_1098 on the microbiota obtained from cecal contents in AP mice.**

**a** OTU Rank-Abundance curves. Different samples are represented by curves of different colors. The abscissa is the number rank sorted by OTU abundance, and the ordinate is the corresponding OTU abundance. **b** Pan analysis. **c** Core analysis. Sobs (**d**), chao (**e**), ace (**f**), shannon (**g**), simpson (**h**), and coverage (**i**) index on OUT level. **j** Rarefaction curves for evaluation of microbial richness. **k** The microbiota beta diversity of group Control, AP, and AP+Amuc\_1098.



**Supplementary Fig. 13: Gating strategy for flow cytometry.** Cells were sequentially gated on lymphocytes (FSC/SSC), live cells (FVD), CD45<sup>+</sup> leukocytes, and finally CD11b<sup>+</sup>F4/80<sup>+</sup> macrophages. Representative plots are shown. These gates correspond to the FACS data in Figure 4a.

**Supplementary Table 1. Specific primer sequences**

| Gene Name          | Primer sequence           |                          |
|--------------------|---------------------------|--------------------------|
|                    | Forward                   | Reverse                  |
| Mus-TNF- $\alpha$  | CCCTCACACTCACAAACCAC      | ACAAGGTACAACCCATCGGC     |
| Mus-IL-6           | GAGGATACCACTCCCAACAGACC   | AAGTGCATCATCGTTGTTCATACA |
| Mus-IL-1 $\beta$   | GCCACCTTTTGACAGTGATGAG    | ATGTGCTGCTGCGAGATTTG     |
| Mus-TLR2           | ACAGCAAGGTCTTCCTGGTTCC    | GCTCCCTTACAGGCTGAGTTCT   |
| Mus-GAPDH          | AGGTCGGTGTGAACGGATTTG     | TGTAGACCATGTAGTTGAGGTCA  |
| Homo-TNF- $\alpha$ | CTCTTCTGCCTGCTGCACTTTG    | ATGGGCTACAGGCTTGTCCTC    |
| Homo-IL-6          | AGACAGCCACTCACCTCTTCAG    | TTCTGCCAGTGCCTCTTTGCTG   |
| Homo-IL-1 $\beta$  | CCACAGACCTTCCAGGAGAATG    | GTGCAGTTCAGTGATCGTACAGG  |
| Homo-TLR2          | CTTCACTCAGGAGCAGCAAGCA    | ACACCAGTGCTGTCCTGTGACA   |
| Homo-GAPDH         | GTCTCCTCTGACTTCAACAGCG    | ACCACCCTGTTGCTGTAGCCAA   |
| Rat-TNF- $\alpha$  | TGAAATGCCACCTTTTGACAGTGAT | GCCTGCCTGAAGCTCTTGTTG    |
| Rat-IL-6           | TAGTCCTTCCTACCCCAATTTCC   | TTGGTCCTTAGCCACTCCTTC    |
| Rat-IL-1 $\beta$   | TGAAATGCCACCTTTTGACAGTGAT | GCCTGCCTGAAGCTCTTGTTG    |
| Rat-TLR2           | GATCCAGAGCAAACTCTCAACAT   | CTCCAGACCATGAAGTTGACAAAC |
| Rat-GAPDH          | TGGAGTCTACTGGCGTCTT       | TGTCATATTTCTCGTGTTCA     |

**Supplementary Table 2. Antibodies**

| Antibodies                                                       | Use          | Source                    | Identifier |
|------------------------------------------------------------------|--------------|---------------------------|------------|
| $\beta$ -tubulin Antibody                                        | Western Blot | Cell Signaling Technology | #2146      |
| NF- $\kappa$ B p65 (D14E12) XP® Rabbit mAb                       | Western Blot | Cell Signaling Technology | #8242      |
| Phospho-NF- $\kappa$ B p65 (Ser536) (93H1) Rabbit mAb            | Western Blot | Cell Signaling Technology | #3033      |
| IKK $\alpha$ (3G12) Mouse mAb                                    | Western Blot | Cell Signaling Technology | #11930     |
| IKK $\beta$ (D30C6) Rabbit mAb                                   | Western Blot | Cell Signaling Technology | #8943      |
| I $\kappa$ B $\alpha$ (L35A5) Mouse mAb (Amino-terminal Antigen) | Western Blot | Cell Signaling Technology | #4814      |
| Phospho-I $\kappa$ B $\alpha$ (Ser32) (14D4) Rabbit mAb          | Western Blot | Cell Signaling Technology | #2859      |
| GAPDH (14C10) Rabbit mAb                                         | Western Blot | Cell Signaling Technology | #2118      |
| CD2AP Antibody                                                   | Western Blot | Cell Signaling Technology | #2135      |
| Claudin-1 (D5H1D) XP® Rabbit mAb                                 | Western Blot | Cell Signaling Technology | #13255     |
| Claudin-3 (D7A3O) Rabbit mAb                                     | Western Blot | Cell Signaling Technology | # 83609    |
| Occludin (E6B4R) Rabbit mAb                                      | Western Blot | Cell Signaling Technology | # 91131    |
| ZO-1 (D7D12) Rabbit mAb                                          | Western Blot | Cell Signaling Technology | #8193      |
| ZO-2 Antibody                                                    | Western Blot | Cell Signaling Technology | #2847      |
| ZO-3 (D57G7) XP® Rabbit mAb                                      | Western Blot | Cell Signaling Technology | #3704      |
| Toll-like Receptor 2 (D7G9Z) Rabbit Monoclonal Antibody          | Western Blot | Cell Signaling Technology | #12276     |
| Toll-like Receptor 2 (E1J2W) Rabbit Monoclonal Antibody          | Western Blot | Cell Signaling Technology | #13744     |